SIHUAN PHARM (00460): New specification of skin booster injection (trade name: Dongyan) approved for marketing by the National Medical Products Administration

SIHUAN PHARM (00460) announced that five new specifications of the sodium hyaluronate composite solution for injection (skin booster injection, or the Product, trade name: Dongyan), independently developed by Meiyan Space Biotechnology (Jilin) Co., Ltd. (Meiyan Space), a subsidiary of the Group, have officially been approved for marketing by China's National Medical Products Administration. The approval of these new specifications marks an important milestone following the Product's launch, further solidifying the Group's product layout and competitiveness in the light medical aesthetics skin booster segment. As the first domestically developed composite solution skin booster injection containing L-carnosine for direct facial use, Dongyan's core ingredients include hyaluronic acid, L-carnosine, multiple amino acids, and vitamin B2, among other active components. It offers multiple benefits including hydration and moisturizing, antioxidant, anti-glycation, and anti-inflammatory effects, as well as promoting collagen regeneration. It is administered via intradermal facial injection to effectively improve skin dryness and dullness, catering to the general public's light medical aesthetics skincare needs and covering a broad consumer base. Prior to this specification expansion, the Product's approved specifications included seven options: 0.5mL/vial, 1.0mL/vial, 1.5mL/vial, 2.0mL/vial, 2.5mL/vial, 3.0mL/vial, and 5mL/box (containing 2 vials of 2.5mL/vial). The five newly approved specifications are 0.75mL/vial, 1.25mL/vial, 1.75mL/vial, 2.25mL/vial, and 2.75mL/vial, effectively filling the gaps in the original dosage range and forming a complete, gradient product dosage spectrum with comprehensive coverage. The main value and significance of this specification expansion: 1. Adapting to diverse skin needs and enriching clinical application scenarios: The new specifications fill the dosage gaps of the original product and can accommodate various clinical scenarios including localized precision shallow-layer care, full-face basic maintenance, and combination regenerative filling treatments. They provide clinicians with more refined dosage options tailored to different facial treatment areas, skin dullness conditions, and individual tolerance differences among consumers, better matching the personalized skin improvement needs of consumers across different age groups and skin conditions. 2. Improving product matrix construction and strengthening synergistic advantages in the segment: As a core essential category in light medical aesthetics, skin booster products are characterized by broad market space and strong user repurchase attributes. China's light medical aesthetics skin booster market segment continues to develop steadily, with industry consumption and clinical demand gradually upgrading toward standardization and personalization. With the full implementation of Dongyan's complete gradient dosage product matrix, it can strengthen business synergies with the Group's other product categories including botulinum toxin, collagen stimulator,, and gold microneedle, flexibly combining to form "filling and regeneration + skin quality repair" integrated anti-aging solutions. Leveraging a mature marketing channel network covering over 370 cities and partnering with over 9,000 medical institutions nationwide, this will further solidify Meiyan Space's full-category operational advantages and market competitiveness in the light medical aesthetics sector. 3. Facilitating standardized and refined industry development: As domestic medical aesthetics consumption concepts continue to upgrade, industry services have gradually shifted from traditional models toward customized, differentiated personalized treatment plans. The approval and launch of these gradient dosage specifications can provide effective reference for the specification R&D and product iteration of similar Class III medical device skin booster products in China, helping to promote high-quality and refined industry development. Meiyan Space is a "one-stop" innovative medical aesthetics platform carefully incubated by SIHUAN PHARM. Through a global layout, a comprehensive and professional medical aesthetics product matrix, and an integrated architecture spanning product R&D, registration, manufacturing, and sales, it is committed to building a leading enterprise in China's medical aesthetics full-product matrix with the rigorous innovation of a pharmaceutical company. Meiyan Space continues to build a complete product matrix covering the full lifecycle needs of beauty enthusiasts through a "self-research + BD" dual-engine drive, with over 60 products in its pipeline covering fundamental light medical aesthetics categories including filling, contouring, support, optoelectronic devices, and skin management. Meanwhile, Meiyan Space possesses strong independent R&D and technology transfer capabilities, and its professional BD teams and R&D teams both domestically and internationally can rapidly advance the development and launch of medical aesthetics products. Currently, Meiyan Space has established three production bases globally, with a comprehensive quality management system and effective risk management throughout the product lifecycle. Its experienced medical aesthetics sales team, nationwide broad-coverage sales network, and deep development system can rapidly advance product sales. Most members of Meiyan Space's sales team come from multinational medical aesthetics and pharmaceutical companies, possessing extensive experience in medical aesthetics product sales, and working closely with dozens of distributors, with a sales network covering over 370 cities and over 9,000 medical aesthetics institutions nationwide.